Safety of current antiviral drugs for chronic hepatitis B

Masetti, Chiara; Pugliese, Nicola Riccardo; Aghemo, Alessio; Viganò, Mauro

doi:10.1080/14740338.2022.2045271

Cited by 4 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retrospective Chen et al, [8] Ha et al, [10] Kim et al, [13] Papatheodoridis et al, [17] Pol et al, [18] Su et al, [20] Na et al, [15] observing the general characteristics of the literature, we found that the age patients in the ETV group are older than that of the TDF group) and follow-up time (the follow-up time of ETV is longer than that of the TDF group) of ETV group and TDF group are both different. In clinical practice, clinicians will prescribe ETV to patients with kidney damage or chronic diseases related to kidney diseases, and will preferentially prescribe ETV to patients with severe liver disease when they consider that long-term use of TDF is associated with kidney damage, [33] resulting in the younger age of patients in the TDF group, their liver disease is milder, and they have no kidney-related disease, which is in favor of TDF to reduce the risk of HCC. Besides, as the viral of the risk of HCC, HBV genotyping, especially gene C typing, owns a higher risk of HCC, the included studies in this meta-analysis do not mention such an issue.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B

et al. 2023

View full text Add to dashboard Cite

Background: Tenofovir and Entecavir are recommended as the first-line medicine of treatment for chronic hepatitis B. The occurrence of hepatocellular carcinoma after the treatment of chronic hepatitis B is a major problem. For the time being it is still unclear whether there remains a difference in risk correlation of hepatocellular carcinoma after the treatment of Tenofovir and Entecavir for chronic hepatitis B. Since previous studies have raised different ideas, this article aims to come to a conclusion targeting such a topic through analyzing the latest data. Methods: We searched some databases, such as PubMed, Web of Science, and Cochrane Library, for related studies on patients with chronic hepatitis B receiving the treatment of Tenofovir and Entecavir and then developing hepatocellular carcinoma. The search time was set to begin from the establishment time of the above-mentioned databases to May 2022. Two researchers were designated to screen the literature independently according to the inclusion and exclusion criteria set in this study; they then evaluated the quality of the literature included and extracted the data. Revman 5.3 software was used for meta-analysis. Results: After screening the literature, a total of 20 pieces of cohort study literature conformed to the inclusion criteria. Among which were 62,860 cases of patients receiving Entecavir, and 27,544 cases of patients receiving Tenofovir; there were 3669 cases with the occurrence of hepatocellular carcinoma in the Entecavir group and 1089 cases with the occurrence of hepatocellular carcinoma in Tenofovir group. The result of Meta analysis of these 20 pieces of literature shows that compared with the Tenofovir group, the Entecavir group has a lower occurrence rate of hepatocellular carcinoma, and the difference is statistically significant. The results are expressed as odd ratio (OR) and 95% confident interval (95%CI), (OR = 1.66, 95%CI: 1.35–2.05, P < .05). The result of Meta analysis of 10 studies related to Korea shows that the occurrence rate of hepatocellular carcinoma in the Tenofovir group is lower than that of the Entecavir group, and the difference is statistically significant (OR = 1.59, 95%CI: 1.29–1.95, P < .05). The result of meta-analysis of 5 studies related to China shows that the occurrence rate of hepatocellular carcinoma of Tenofovir group is lower than that of Entecavir group, and the difference is statistically significant (OR = 2.35, 95%CI: 1.15–4.81, P < .05). Conclusion: The occurrence rate of hepatocellular carcinoma after the treatment of tenofovir for chronic hepatitis B is lower than that of the treatment of entecavir.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Notable reductions in cirrhosis and hepatocellular carcinoma and the prevention of vertical transmission were associated with the U.S. Food and Drug Administration–approved TFV therapy for CHB ( 21 ). We posit that further improved treatment outcomes can be achieved using long-acting injectable formulations.…”

Section: Discussionmentioning

confidence: 99%

An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression

et al. 2022

View full text Add to dashboard Cite

Treatment of chronic hepatitis B virus (HBV) requires lifelong daily therapy. However, suboptimal adherence to the existing daily therapy has led to the need for ultralong-acting antivirals. A lipophilic and hydrophobic ProTide was made by replacing the alanyl isopropyl ester present in tenofovir alafenamide (TAF) with a docosyl phenyl alanyl ester, now referred to as M1TFV. NM1TFV and nanoformulated TAF (NTAF) nanocrystals were formulated by high-pressure homogenization. A single intramuscular injection of NM1TFV, but not NTAF, delivered at a dose of TFV equivalents (168 milligrams per kilogram) demonstrated monthslong antiviral activities in both HBV-transgenic and human hepatocyte transplanted TK-NOG mice. The suppression of HBV DNA in blood was maintained for 3 months. Laboratory experiments on HBV-transfected HepG2.2.15 cells affirmed the animal results and the critical role of docosanol in the sustained NM1TFV antiviral responses. These results provide clear “proof of concept” toward an emerging therapeutic paradigm for the treatment and prevention of HBV infection.

show abstract

Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B

Yip,

Lai,

Yam

et al. 2024

Journal of Hepatology

View full text Add to dashboard Cite

Safety of current antiviral drugs for chronic hepatitis B

Cited by 4 publications

References 50 publications

Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B

Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B

An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression

Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B

Contact Info

Product

Resources

About